Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558439 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain
A Phase 2 study of Osteoarthritis, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT02558439 is a Phase 2 study of Osteoarthritis that has completed, run by Centrexion Therapeutics. The registered enrollment target is 175 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02558439, a Phase 2 study of Osteoarthritis, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CNTX-4975
Study Locations (20)
Florida
- Avail Clinical Research, LLC - DeLand
- Finlay Research Clinic - Hialeah
- Eastern Research - Hialeah
- Sunrise Medical Research - Lauderdale Lakes
- M&M Medical Center, Inc - Miami
- Compass Research, LLC - Orlando
- Compass Research, LLC - The Villages
California
- Dream Team Clinical Research, LLC - Anaheim
- Hope Clinical Research, LLC - Canoga Park
- TriWest Research Associates - El Cajon
- BioSolutions Clinical Research Center - La Mesa
- Axis Clinical Trials - Los Angeles
New York
- Drug Trials America - Hartsdale
- Manhattan Medical Research Practice - New York
Alabama
- Achieve Clinical Research, LLC - Birmingham
Arizona
- Advanced Arizona Clinical Research - Tucson
Georgia
- Clinical Research Atlanta - Stockbridge
Missouri
- The Center for Pharmaceutical Research - Kansas City
North Carolina
- Wake Research Associates, LLC - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558439
The ClinicalTrials.gov registry entry for NCT02558439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (79% lower). The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02558439 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT02558439 about?
NCT02558439 is a clinical study titled "Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain". The purpose of this study is to evaluate the safety and efficacy of a single injection of CNTX-4975 in subjects with chronic, moderate to severe osteoarthritis knee pain.
What is the current status of trial NCT02558439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2015-08. Estimated completion is 2017-02.
What conditions does trial NCT02558439 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT02558439?
The interventions under investigation include: Placebo (OTHER), CNTX-4975 (DRUG).
Who is sponsoring clinical trial NCT02558439?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02558439 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.